Mesa Laboratories, Inc. - 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Mesa Laboratories, Inc., a smaller reporting company, for the period ended December 31, 2009. The company manufactures and distributes electronic measurement systems and disposables for niche applications including renal treatment, food processing, medical sterilization, and pharmaceutical processing.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2009 | Nine Months Ended Dec 31, 2009 |
|---|---|---|
| Net Sales | $5,318,000 | $15,702,000 |
| Net Income | $1,154,000 | $3,424,000 |
| Diluted EPS | $0.35 | $1.04 |
| Gross Margin | 62.0% | 61.1% |
| Operating Cash Flow (9mo) | $4,882,000 | |
| Cash & Equivalents (End of Period) | $9,940,000 | |
| Total Debt | $0 (No long-term debt or lines of credit) | |
| Current Ratio | 11:1 |
Material Changes vs. Prior Period
- Revenue: Net sales for the three months ended Dec 31, 2009, decreased slightly ($19,000 or <1%) compared to the prior year. For the nine-month period, sales decreased 2% ($369,000) to $15.7 million.
- Profitability: Net income decreased 5% for both the quarter and the nine-month period compared to the prior year. This was driven by a shift in product mix (higher sales of lower-margin Raven products vs. DataTrace) and lower interest income on surplus cash.
- Acquisition: On December 18, 2009, the company acquired the bottle cap torque testing product line of Vibrac LLC for approximately $2.66 million. This contributed minimally to Q3 sales due to timing.
- Cost Structure: Cost of sales as a percentage of net sales increased to 38.0% for the quarter (from 35.7% prior year) and 38.9% for the nine-month period (from 36.0% prior year). However, Selling, General & Administrative (SG&A) expenses decreased significantly, offsetting some margin pressure.
Outlook, Risks, and Management Commentary
- Product Mix Impact: Management notes that profitability is sensitive to the mix between DataTrace (higher margin) and Raven (lower margin) products. Recent trends show a shift toward Raven sales, impacting overall margins.
- Capital Allocation: The company maintains a strong cash position ($9.94M) with no debt. It continues a share repurchase program (up to 300,000 shares authorized) and pays regular quarterly dividends (most recent: $0.11/share).
- Risks: Key risks include general economic conditions affecting capital spending, competition in data logging and medical markets, and the successful integration of the new Vibrac product line.
- Subsequent Events: The company evaluated subsequent events through February 16, 2010. No material subsequent events were disclosed other than the ongoing integration of the Vibrac acquisition.
Investor Verification Checklist
- Verify the impact of the Vibrac LLC acquisition on future revenue streams and integration costs.
- Monitor the product mix shift between DataTrace and Raven lines to assess future gross margin trends.
- Review the share repurchase activity and dividend sustainability given the current cash burn rate for acquisitions and buybacks.
- Confirm the valuation of intangible assets ($2.38M) recorded from the Vibrac acquisition as the company finalizes fair value estimates.